SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alivus Life Sciences - Quaterly Results

23 Jan 2025 Evaluate
The revenue for the December 2024 quarter is pegged at Rs. 6418.44 millions, about 12.05% up against Rs. 5728.04 millions recorded during the year-ago period.Profit saw a slight increase of 15.32%to Rs. 1369.60  millions from Rs. 1187.65 millions.The company reported a good operating profit of 2007.64 millions compared to 1742.47 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 6418.44 5728.04 12.05 17373.39 17466.17 -0.53 22832.14 21612.20 5.64
Other Income 104.56 16.91 518.33 244.82 89.11 174.74 120.42 289.57 -58.41
PBIDT 2007.64 1742.47 15.22 5086.34 5417.12 -6.11 6862.88 6712.50 2.24
Interest 4.58 3.87 18.35 11.54 11.82 -2.37 15.46 5.47 182.63
PBDT 2003.06 1738.60 15.21 5074.80 5405.30 -6.11 6847.42 6707.03 2.09
Depreciation 151.59 131.77 15.04 446.39 389.18 14.70 534.52 420.94 26.98
PBT 1851.47 1606.83 15.23 4628.41 5016.12 -7.73 6312.90 6286.09 0.43
TAX 481.87 419.18 14.96 1190.82 1286.60 -7.44 1604.02 1616.48 -0.77
Deferred Tax 13.81 30.57 -54.82 45.19 75.00 -39.75 81.88 110.37 -25.81
PAT 1369.60 1187.65 15.32 3437.59 3729.52 -7.83 4708.88 4669.61 0.84
Equity 245.07 245.05 0.01 245.07 245.05 0.01 245.05 245.05 0.00
PBIDTM(%) 31.28 30.42 2.82 29.28 31.01 -5.60 30.06 31.06 -3.22

Alivus Life Sciences Share Price

1066.65 -6.50 (-0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×